Korean Biotech Talks About U.S. Company Launch

Author(s):

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

He spoke to Pharm Exec during a company event in New York City.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Videos